MRC1 and Leigh syndrome: This will inevitably lead to increased LS detection [70], and will facilitate germline MMR gene testing of select patients whilst still under acute care, allowing identified LS cases to benefit from not only immune checkpoint blockade therapy [3], but other acute clinical interventions such as more extensive surgery to reduce risk of metachronous disease [264].